Cardiovascular Clinical Trials Market Analysis

Phase (Phase I, Phase II, Phase III, Phase IV)

Phase IV segment is set to account for more than 32% cardiovascular clinical trials market share by the end of 2037. The segment growth can be attributed to regulatory bodies such as the U.S. FDA and European Union regulatory authorities requiring post-marketing research to ensure the efficacy and safety of cardiovascular devices. Compliance with these criteria drives the conduct of Phase IV trials, boosting the segment’s growth. For instance, PubMed discovered 4,772 Phase IV trials sponsored by the National Institutes of Health, with 330 focusing solely on medication safety and 4,392 assessing both safety and efficacy. Of these trials, 8.2% were canceled or delayed.

 In addition, the proliferation of patient data and advances in genomics are increasing research to investigate the benefits of incorporating global data into clinical trials. The intervention model, therapeutic specialty, and principal sponsor were all factors that influenced the use of blinding and randomization. Also, as experts across the industry say, global data are actively integrated with Phase IV clinical trials to obtain payer approvals and evaluation of clinical interventions. Hence, the aforementioned trends are expected to increase the demand for phase IV trials, thereby increasing the growth of the segment in the cardiovascular clinical trials market.

Study Design (Interventional, Observational, Expanded Access)

By 2037, interventional segment is expected to capture over 48% cardiovascular clinical trials market share. Growing interventional research, with chemical or biological including biological, behavioral, surgical techniques, and devices is set to expand the segment’s growth. In a recent study in the New England Journal of Medicine in 2022, of the 10,596 patients presenting to the emergency department with acute myocardial infarction, 7899 patients were eligible for inclusion in the trial. After excluding those who had reasons for not attending the RAPID-HF clinic, 5452 patients were enrolled in the trial (2972 in the control period, 2480 in the intervention period in the 19th century).

There has been a significant increase in the number of interventional studies developed over time. Interventional studies are generally preferred over observational studies because of their greater accuracy and relevance. Furthermore, for clinical trials of a cardiovascular device, interventional research is the gold standard, and supports, the accuracy and efficiency of the medical device under study large share of the market.

Therapeutic Area (Oncology, Cardiology, Neurology)

Cardiology dominates the segment taking 48% of the cardiovascular clinical trials market in the upcoming years. Robust growth in this segment is witnessed due to factors such as the growing incidence of CVD, the aging population globally, as well as the strategic collaboration between the pharma and biotech companies in which the latter is mainly involved in cardiovascular disease (CVD).

According to the World Heart Association Report 2023, more than half a billion people worldwide are affected by cardiovascular disease, including 20.5 million deaths by 2021, approximately one-third of global deaths, and an estimated million-person increase of 121 CVD deaths. This has led to the search for conventional drugs for the treatment of heart failure, which leads to the identification of clinical trial sites for the same.

Our in-depth analysis of the cardiovascular clinical trials market includes the following segments: